NAD+ Research Shows Promise for Alzheimer's Treatment

A groundbreaking study published in Brain: A Journal of Neurology has revealed a novel mechanism by which NAD+ (nicotinamide adenine dinucleotide) may help combat Alzheimer's disease pathology. Researchers led by Lagartos-Donate and colleagues discovered that NAD+ can restore the function of a critical brain protein called REST, potentially offering new therapeutic avenues for neurodegenerative disease treatment.

What This Study Found

The research team investigated the role of REST (Repressor Element 1-Silencing Transcription factor) in Alzheimer's disease progression by examining brain tissue samples from the entorhinal cortex and hippocampus across different stages of tau protein pathology, known as Braak stages.

The study found that REST expression becomes progressively downregulated and inactivated as Alzheimer's disease advances. This protein normally serves as a crucial regulator of gene expression in the brain, particularly genes involved in maintaining healthy mitochondria and synaptic connections between neurons.

When researchers experimentally restored REST function, they observed remarkable improvements: enhanced cognitive function, reduced amyloid-β plaques, decreased phosphorylated tau deposits, and restoration of both mitochondrial and synaptic health. These findings suggest that REST dysfunction may be a central mechanism driving Alzheimer's pathology.

Most significantly, the researchers discovered that NAD+ works through the SIRT1 pathway to modulate REST expression. This occurs through chromatin remodeling in the REST gene's promoter region, ultimately affecting the expression of REST target genes that are crucial for mitophagy (the cellular process of removing damaged mitochondria) and synaptic function.

Clinical Significance

This research provides important insights into potential therapeutic mechanisms for Alzheimer's disease treatment. The study suggests that targeting the NAD+/SIRT1/REST pathway could offer a multi-faceted approach to addressing several hallmarks of Alzheimer's pathology simultaneously.

The findings are particularly significant because they demonstrate that NAD+ supplementation may work through a previously unknown mechanism. Rather than simply supporting cellular energy metabolism, the study suggests NAD+ may help restore the brain's natural protective mechanisms by reactivating REST function.

However, it's crucial to note that while these results are promising, human clinical trials are needed to determine whether NAD+ supplementation can produce similar benefits in Alzheimer's patients. The mechanisms identified in this study provide a strong scientific rationale for pursuing such trials.

Current Access and Compliance Context

NAD+ and its precursors, including nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), are available as dietary supplements in the United States. These compounds are regulated by the FDA as dietary supplements rather than pharmaceutical drugs, meaning they do not require prescription access.

Several NAD+ precursor supplements have been studied in clinical trials for various age-related conditions, though specific research on Alzheimer's disease in humans remains limited. The current study provides mechanistic evidence that may support future clinical investigations.

Healthcare providers interested in NAD+ therapy for patients should be aware that while generally considered safe, NAD+ precursors can interact with certain medications and may not be appropriate for all patients. Proper medical oversight is recommended when considering NAD+ supplementation, particularly in patients with existing medical conditions.

What Patients Should Know

For patients and families affected by Alzheimer's disease, this research offers hope while underscoring the importance of evidence-based treatment approaches. The study suggests that NAD+ may work through sophisticated cellular mechanisms that go beyond simple nutritional support.

However, patients should understand that this research does not yet translate to proven clinical benefits in humans. The study's findings represent important mechanistic insights that require validation through properly designed clinical trials before making definitive treatment recommendations.

Patients considering NAD+ supplementation should discuss this option with their healthcare provider, particularly if they are taking medications or have underlying health conditions. NAD+ supplementation should be viewed as complementary to, not replacement for, established medical care for cognitive health.

It's also important to note that lifestyle factors such as regular exercise, adequate sleep, and a healthy diet naturally support NAD+ levels and may work synergistically with supplementation approaches.

The research timeline for translating these findings into clinical practice typically requires several years of human studies. Patients interested in participating in clinical trials investigating NAD+ for Alzheimer's disease should consult with their neurologist about available research opportunities.

For patients interested in exploring NAD+ therapy options, consultation with a qualified healthcare provider experienced in peptide and regenerative medicine is essential. Find a qualified provider through the Peptide Association directory to discuss whether NAD+ therapy might be appropriate for your individual situation.

This article is for educational purposes only and is not intended as medical advice. Always consult with a qualified healthcare provider before making decisions about your health or treatment options. The research discussed represents preliminary findings that require further validation in human clinical trials.

Citation: Lagartos-Donate MJ, Escobar-Doncel B, Zhang SQ, et al. Loss of REST associated with Alzheimer's disease pathology is ameliorated by NAD. Brain. 2026;041709697. doi:10.1093/brain/awaf261